Gastroesophageal reflux disease, resistant to proton pump inhibitors
Abstract
The aim of review. To discuss the factors, promoting development of resistance at treatment of gastroesophageal reflux disease (GERD), and possible means to overcome it.
Original positions. Pharmacological therapy of GERD is focused on change of refluxate properties besides decreasing of its volume and aggressive properties by such classes of drugs, as antacids, alginates and hydrochloric acid secretion inhibitors. However for today frequency of clinical resistance in GERD patients reaches 10–40%. The causes of resistance to antisecretory therapy are inadequate acid suppression, weakly acidic refluxes, duodenogastroesophageal reflux, psychological features of patients, etc. Potentials of treatment of the patients with sustained symptoms of GERD on a background of standard dose of proton pump inhibitors (PPI), include correction drug intake, doubling of PPI dose, application of intravenous forms, combination of antisecretory agents of different groups, addition to therapy of drugs, capable to adsorb bile components and modulation of psychoemotional status of patients.
Conclusion. Despite of significant progress in treatment of acid-related diseases the problem of resistance of significant part of GERD patients to antisecretory therapy is still actual.
About the Authors
V. O. Kaybysheva
ГОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова Росздрава»
Russian Federation
Russian Federation
A. S. Trukhmanov
ГОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова Росздрава»
Russian Federation
Russian Federation
V. T. Ivashkin
ГОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова Росздрава»
Russian Federation
Russian Federation
References
1. Буеверов О.А., Лапина Т.Л. Дуоденогастроэзофагеа льный рефлюкс как причина рефлюкс-эзофагита // Фарматека. – 2006. – № 1. – С. 22–27.
2. Ивашкин В.Т., Трухманов А.С. Современный подход к терапии гастроэзофагеальной рефлюксной болезни во врачебной практике // Рус. мед. журн. – 2003. – Т. 11, № 2. – С. 43–48.
3. Маев И.В., Трухманов А.С. Лекарственная терапия неэрозивной рефлюксной болезни // Рус. мед. журн. – 2004. – Т. 12, № 24. – С. 1402–1409.
4. Трухманов А.С. Гастроэзофагеальная рефлюксная болезнь: клинические варианты, прогноз, лечение: Автореф. ... д-ра мед. наук. – М., 2008. – 41 с.
5. Шептулин А.А. Современные возможности и перспективы лечения резистентных форм гастроэзофагеальной рефлюксной болезни // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2010. – Т. 20, № 6. – С. 81–85.
6. Arvanitakis C., Nikopoułos A., Theoharidis A. et al. Cisapride and ranitidine in the treatment of gastroesophageal reflux disease – a comparative randomized double-blind trial // Aliment. Pharmacol. Ther. – 1993. – Vol. 7, N 6. – P. 635–641.
7. Barrison A.F., Jarbe L.A., Weinberg M.D. et al. Patterns of proton pump inhibitors in clinical practice // Am. J. Med. – 2001. – Vol. 111. – P. 469–473.
8. Bell N.J., Burget D., Howden C.W. et al. Appropriate acid suppression for the management of gastroesophageal reflux disease // Digestion. – 1992. – Vol. 51 (suppl. 1). – P. 59–67.
9. Carlsson R., Dent J., Watts R. et al. Gastroesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group // Eur. J. Gastroenterol. Hepatol. – 1998. – Vol. 10. – P. 119–124.
10. Crawley J.A., Schmitt C.M. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the Patient Unmet Needs Study // J. Clin. Outcomes Manag. – 2000. – Vol. 7. – P. 29–34.
11. Dean B.B., Gano A.D.Jr., Knight K. et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease // Clin. Gastroenterol. Hepatol. – 2004. – Vol. 2. – P. 656–664.
12. DeVault K.R., Castell D.O. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease // Am. J. Gastroenterol. – 2005. – Vol. 100. – P. 190–200.
13. Drossman D. Rome III: The functional gastrointestinal disorders. – 3rd ed. – McLean, VA: Degnon Associates, Inc., 2006. – P. 369–418.
14. Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics // J. Clin. Gastroenterol. – 2007. – Vol. 41. – P. 131–137.
15. Fass R., Murthy U., Hayden C.W. et al. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastroesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy – a prospective, randomized, multi-centre study // Aliment. Pharmacol. Ther. – 2000. – Vol. 14. – P. 1595–603.
16. Fass R., Shapiro M., Dekel R. et al. Systematic review: proton pump inhibitor failure in gastroesophageal reflux disease –where next? // Aliment. Pharmacol. Ther. – 2005. – Vol. 22. – P. 79–94.
17. Fass R., Sifrim D. Management of heartburn not responding to proton pump inhibitors // Gut. – 2009. – Vol. 58. – P. 295–309.
18. Frieling T. Anti reflux therapy – more than acid reduction // Internist (Berl). – 2004. – Vol. 45. – P. 1364–1369.
19. Furuta T., Shirai N., Watanabe F. et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprasole // Clin. Pharmacol. Ther. – 2002. – Vol. 72. – P. 453–460.
20. Galmiche J.P., Barthelemy P., Hamelin B. Treating the symptoms of gastroesophageal reflux disease: a doubleblind comparison of omeprazole and cisapride // Aliment. Pharmacol. Ther. – 1997. – Vol. 11, N 4. – P. 765–773.
21. Gunaratnam N.T., Jessup T.P., Inadomi J. et al. Suboptimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastroesophageal reflux disease // Aliment. Pharmacol. Ther. – 2006. – Vol. 23. – P. 1473–1477.
22. Guslandi M., Testoni P.A., Passaretti S. et al. Ranitidine vs metoclopramide in the medical treatment of reflux esophagitis // Hepatogastroenterology. – 1983. – Vol. 30, N 3. – P. 96–98.
23. Handa M., Mine K., Yamamoto H. et al. Antidepressant treatment of patients with diffuse esophageal spasm: a psychosomatic approach // J. Clin. Gastroenterol. – 1999. – Vol. 28. – P. 228–232.
24. Hatlebakk J.G., Katz P.O., Camacho-Lobato L. et al. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal // Aliment. Pharmacol. Ther. – 2000. – Vol. 14. – P. 1267–1272.
25. Hershcovici T., Fass R. Nonerosive Reflux Disease (NERD) – An Update // J. Neurogastroenterol. Motil. – 2010. – Vol. 16, N 1. – P. 8–21, 39.
26. Hungin A.P.S., Rubin G., O’Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice // Br. J. Gen. Pract. – 1999. – Vol. 49. – P. 463–464.
27. Inadomi J.M., McIntyre L., Bernard L. et al. Stepdown from multipleto single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs // Am. J. Gastroenterol. – 2003. – Vol. 98. – P. 1940–1944.
28. Miwa H., Minoo T., Hojo M. et al. Oesophageal hypersensitivity in Japanese patients with non-erosive gastroesophageal reflux diseases // Aliment. Pharmacol. Ther. – 2004. – Vol. 20 (suppl. 1). – P. 112–117.
29. Modlin, Hunt, Malfertheiner et al. Diagnosis and management of non-erosive reflux disease –The Vevey NERD Consensus Group // Digestion. – 2009. – Vol. 80. – P. 74–88.
30. Nagahara A., Miwa H., Minoo T. et al. Increased esophageal sensitivityto acid and saline in patients with nonerosive gastroesophageal reflux disease // J. Clin. Gastroenterol. – 2006. – Vol. 40. – P. 891–895.
31. Orr W.C. Reflux events and sleep: are we vulnerable? // Curr. Gastroenterol. Rep. – 2006. – Vol. 8. – P. 202–207.
32. Pazzi P. et al. Bile reflux gastritis in patients without prior gastric surgery: therapeutic effects of ursodeoxycholic acid // Curr. Ther. Res. – 1989. – Vol. 45. – P. 476–487.
33. Peghini P.L., Katz P.O., Bracy N.A., Castell D.O. Nocturnal recovery of gastric acid secretion with twicedaily dosing of proton pump inhibitors // Am. J. Gastroenterol. – 1998. – Vol. 93. – P. 763–767.
34. Pezanoski J., Guanaratnam N., Cowen M. Correct and incorrect dosing of proton pump inhibitors and its impact on GERD symptoms // Gastroenterology. – 2003. – Vol. 124 (suppl.). – P. 128.
35. Ramirez B., Richter J.E. Review article: promotility drugs in the treatment of gastro-oesophageal reflux disease // Aliment. Pharmacol. Ther. – 1993. – Vol. 7, N 1. – P. 5–20.
36. Reddy H., Staahl C., Arendt-Nielsen L. et al. Sensory and biomechanical properties of the esophagus in nonerosive reflux disease // Scand. J. Gastroenterol. – 2007. – Vol. 42. – P. 432–440.
37. Tack J., Koek G., Demedts I. et al. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett’s esophagus: acid reflux, bile reflux, or both? // Am. J. Gastroenterol. – 2004. – Vol. 99. – P. 981–989.
38. The Gallup Organization. The 2000 Gallup Study of Consumers’ Use of Stomach Relief Products. – Princeton: Gallup Organization, 2000.
39. Trimble K.C., Pryde A., Heading R.C. Lowered esophageal sensory thresholds in patients with symptomatic but not excess gastroesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD // Gut. – 1995. – Vol. 37. – P. 7–12.
40. Tutuian R., Katz P.O., Castell D.O. Nocturnal acid breakththrough, drugs and bugs // Eur. J. Gastroenterol. Hepatol. – 2004. – Vol. 16. – P. 441–463.
41. Wolfe M.M., Lowe R.C. Investing in the Future of GERD // J. Clin. Gastroenterol. – 2007. – Vol. 41. – P. 209.
42. Yuan Y., Hunt H. Evolving issues in the management of reflux disease? // Curr. Opin. Gastroenterol. – 2009. – Vol. 25, N 4. – P. 342–351.
43. Yuan Y., Hunt R.H. Intragastric acid suppressing effect of proton pump inhibitors twice daily at steady state in healthy volunteers: evidence of an unmet need? // Am. J. Gastroenterol. – 2008. – Vol. 103 (suppl 1). – P. 50. Abstract #128.
44. Yuan Y., Hunt R.H. Intragastric pH holding time pH <3 at steady state in healthy volunteers (HV) after once daily PPIs: a predictor for low erosive esophagitis (EE) healing rates? // Gastroenterology. – 2009. – Vol. 136 (suppl.). Abstract #M1900.
45. Yuan Y., Vinh B., Hunt R.H. Nonhealed rate of moderate-severe (LA Classification Grade C and D) erosive esophagitis after 4–8 weeks proton pump inhibitors (PPIs): evidence of an unmet need // Gastroenterology. – 2009. – Vol. 136 (suppl.). Abstract #M1893.
Review
For citations:
Kaybysheva V.O., Trukhmanov A.S., Ivashkin V.T. Gastroesophageal reflux disease, resistant to proton pump inhibitors. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2011;21(4):4-13. (In Russ.)
Views:
91
Email this article 
